Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06377540 · ClinicalTrials.gov registry record · Phase 2
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
A Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06377540: Recruiting Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant, sponsored by Masonic Cancer Center, University of Minnesota.
NCT06377540 is a Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 28 participants, below the 250-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06377540, a Phase 2 study of Classic Hodgkin Lymphoma and Autologous Stem Cell Transplant, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.
Primary Outcome
Number of participants with progression free survival at 1 year post transplant. Time from date of study enrollment to date of first documented progression, or death. Patients who do not progress or die at the time of analysis will be censored at their last known date alive.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
- PROCEDURE Autologous stem cell transplant
Study Locations (1)
Minnesota
- Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
What NCT06377540 shows while recruiting
NCT06377540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 250-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06377540 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06377540 about?
NCT06377540 is a clinical study titled "MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma". This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell trans...
What is the current status of trial NCT06377540?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-12-04. Estimated completion is 2027-09-01.
What conditions does trial NCT06377540 study?
This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Autologous Stem Cell Transplant.
What interventions are being tested in trial NCT06377540?
The interventions under investigation include: Pembrolizumab (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG), Autologous stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT06377540?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06377540 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classic Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06377540's enrollment target sits among peer trials
28 9th of 9 higher than 1 of 9 other Classic Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Classic Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
RECRUITING · Phase 2
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI